KR20060003362A - 약물부하가 높은 메살라진 포 - Google Patents
약물부하가 높은 메살라진 포 Download PDFInfo
- Publication number
- KR20060003362A KR20060003362A KR1020057020069A KR20057020069A KR20060003362A KR 20060003362 A KR20060003362 A KR 20060003362A KR 1020057020069 A KR1020057020069 A KR 1020057020069A KR 20057020069 A KR20057020069 A KR 20057020069A KR 20060003362 A KR20060003362 A KR 20060003362A
- Authority
- KR
- South Korea
- Prior art keywords
- mesalazine
- granules
- pharmaceutical formulation
- formulation
- oral administration
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/12—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of paper or cardboard
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/04—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B15/08—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin
- B32B15/085—Layered products comprising a layer of metal comprising metal as the main or only constituent of a layer, which is next to another layer of the same or of a different material of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B15/00—Layered products comprising a layer of metal
- B32B15/20—Layered products comprising a layer of metal comprising aluminium or copper
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/06—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material
- B32B27/10—Layered products comprising a layer of synthetic resin as the main or only constituent of a layer, which is next to another layer of the same or of a different material of paper or cardboard
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B27/00—Layered products comprising a layer of synthetic resin
- B32B27/32—Layered products comprising a layer of synthetic resin comprising polyolefins
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B7/00—Layered products characterised by the relation between layers; Layered products characterised by the relative orientation of features between layers, or by the relative values of a measurable parameter between layers, i.e. products comprising layers having different physical, chemical or physicochemical properties; Layered products characterised by the interconnection of layers
- B32B7/04—Interconnection of layers
- B32B7/12—Interconnection of layers using interposed adhesives or interposed materials with bonding properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/20—Properties of the layers or laminate having particular electrical or magnetic properties, e.g. piezoelectric
- B32B2307/21—Anti-static
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/72—Density
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/724—Permeability to gases, adsorption
- B32B2307/7242—Non-permeable
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/724—Permeability to gases, adsorption
- B32B2307/7242—Non-permeable
- B32B2307/7246—Water vapor barrier
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2307/00—Properties of the layers or laminate
- B32B2307/70—Other properties
- B32B2307/726—Permeability to liquids, absorption
- B32B2307/7265—Non-permeable
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2323/00—Polyalkenes
- B32B2323/04—Polyethylene
- B32B2323/046—LDPE, i.e. low density polyethylene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2439/00—Containers; Receptacles
- B32B2439/40—Closed containers
- B32B2439/46—Bags
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B2439/00—Containers; Receptacles
- B32B2439/80—Medical packaging
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/13—Hollow or container type article [e.g., tube, vase, etc.]
- Y10T428/1303—Paper containing [e.g., paperboard, cardboard, fiberboard, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Laminated Bodies (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Wrappers (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
Claims (22)
- 60 중량% 초과의 메살라진(mesalazine) 또는 그의 약학적으로 허용가능한 염을 포함하는 과립형의 경구 투여용 약학적 제형.
- 제 1항에 있어서, 70 중량% 초과의 메살라진 또는 그의 약학적으로 허용가능한 염을 포함하는 것을 특징으로 하는, 과립형의 경구 투여용 약학적 제형.
- 제 1항에 있어서, 80 중량% 초과의 메살라진 또는 그의 약학적으로 허용가능한 염을 포함하는 것을 특징으로 하는, 과립형의 경구 투여용 약학적 제형.
- 제 1항 내지 제 3항 중 어느 한항에 있어서, 37℃의 100 rpm 교반 조건의 USP Paddle 시스템 2를 이용한 모델 시스템에서, 240분 경과시 상기 제형에 함유된 메살라진 총 함량에 대해 40 % 이상의 메살라진이 생체외에서 방출되는 특성을 가지는 것을 특징으로 하는, 과립형의 경구 투여용 약학적 제형.
- 제 1항 내지 제 4항 중 어느 한항에 있어서, 37℃의 100 rpm 교반 조건의 USP Paddle 시스템 2를 이용한 모델 시스템에서,(a) 15분 경과시 상기 제형에 함유된 메살라진 총 함량에 대해 5-25 % 함량의 메살라진이 방출되며;(b) 90분 경과시 상기 제형에 함유된 메살라진 총 함량에 대해 30-70 %, 바람직하게는 40-60 % 함량의 메살라진이 방출되며;(c) 240분 경과시 상기 제형에 함유된 메살라진 총 함량에 대해 75-100 % 함량의 메살라진이 방출되는,생체외 방출 특성을 가지는 것을 특징으로 하는, 과립형의 경구 투여용 약학적 제형.
- 제 1항 내지 제 5항 중 어느 한항에 있어서, 37℃의 100 rpm 교반 조건의 USP Paddle 시스템 2를 이용한 모델 시스템에서,(a) 15분 경과시 상기 제형에 함유된 메살라진 총 함량에 대해 12 % 함량의 메살라진이 방출되며;(b) 90분 경과시 상기 제형에 함유된 메살라진 총 함량에 대해 50 % 함량의 메살라진이 방출되며;(c) 240분 경과시 상기 제형에 함유된 메살라진 총 함량에 대해 85 % 함량의 메살라진이 방출되는,생체외 방출 특성을 가지는 표준물질에 비해, 30 이상, 바람직하기로는 40 이상, 더 바람직하기로는 50 이상의 유사성 인자 f2를 가지는 것을 특징으로 하는, 과립형의 경구 투여용 약학적 제형.
- 제 1항 내지 제 6항 중 어느 한항에 있어서, 약학적으로 허용가능한 결합제, 바람직하기로는 포비돈을 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 및 12 중량%로 이루어진 군으로부터 선택되는 함량 이하로 더 포함하는 것을 특징으로 하는, 과립형의 경구 투여용 약학적 제형.
- 제 1항 내지 제 7항 중 어느 한항에 있어서, 바람직하기로는 에틸셀룰로즈를 포함하는 코팅제 또는 에틸셀룰로즈로 구성된 코팅제를 더 포함하는 것을 특징으로 하는, 과립형의 경구 투여용 약학적 제형.
- 제 1항 내지 제 8항 중 어느 한항에 있어서, 코팅제를 포함하며,상기 메살라진 또는 상기 약학적으로 허용가능한 염에 대한 상기 코팅제의 중량비는 0.1-10 %, 0.3-7 %, 0.5-5 %, 0.7-3 %, 0.8-2 % 및 0.9-1.5%로 이루어진 군으로부터 선택되는 것을 특징으로 하는, 과립형의 경구 투여용 약학적 제형.
- 제 1항 내지 제 9항 중 어느 한항에 있어서, 메살라진, 약학적으로 허용가능한 결합제 및 코팅제를 필수적인 구성요소로 포함하는 것을 특징으로 하는, 과립형의 경구 투여용 약학적 제형.
- 제 1항 내지 제 10항 중 어느 한항에 있어서, 상기 약학적 제형은 포(Sachet)내에 충진된 것을 특징으로 하는, 과립형의 경구 투여용 약학적 제형.
- a) 메살라진을 과립 액체와 혼합하는 단계,b) 과립화, 압축화 또는 압출 성형화로 과립을 수득하는 단계,c) 과립을 건조하는 단계,d) 필요한 경우 과립의 크기를 조절하는 단계,e) 필요한 경우 과립을 체질하는 단계프 포함하며, 추가적로,f) 과립을 코팅하는 단계를 포함하고 또한 다음의 단계들을 선택적으로 포함한다:g) 코팅된 과립을 체질하는 단계,h) 코팅된 과립을 공기 퍼징(purging)하는 단계를 포함하는, 약학적 제형의 제조 방법.
- 제 12항에 있어서, 상기 코팅된 과립을 포에 충진하는 것을 특징으로 하는, 약학적 제형의 제조방법.
- 제 12항 또는 제 13항에 있어서, 상기 과립 액체는 물에 용해된 포비돈으로 구성되는 것을 특징으로 하는, 약학적 제형의 제조방법.
- 제 12항 내지 제 14항중 어느 한항에 있어서, 상기 건조 단계 c)는 유동층 건조기(fluid bed dryer)에서 수행되는 것을 특징으로 하는, 약학적 제형의 제조방 법.
- 제 12항 내지 제 15항중 어느 한항에 있어서, 상기 크기 조절 단계 d)는 밀링(milling)에 의해 수행되는 것을 특징으로 하는, 약학적 제형의 제조방법.
- 제 12항 내지 제 16항중 어느 한항에 있어서, 상기 체질 단계 e)는 1.8 mm 체는 통과하지만 0.5 mm 체는 통과하지 못하는 과립을 선별함으로써 수행되는 것을 특징으로 하는, 약학적 제형의 제조방법.
- 제 12항 내지 제 17항중 어느 한항에 있어서, 상기 코팅 단계 f)는 에틸셀룰로즈를 이용하여 수행되는 것을 특징으로 하는, 약학적 제형의 제조방법.
- 제 12항 내지 제 18항중 어느 한항에 있어서, 상기 코팅 단계 f)는 코팅 물질을 비표면적(specific surface area)에 따라 0.09 - 0.17 mg/cm2, 바람직하기로는 0.11 - 0.15 mg/cm2 범위로 적용하고 건조함으로써 수행되는 것을 특징으로 하는, 약학적 제형의 제조방법.
- 제 12항 내지 제 19항중 어느 한항에 있어서, 상기 체질 단계 g)는 회전 체, 바람직하기로는 2.5 mm 메쉬 크기를 가진 회전 체상에서 수행되는 것을 특징으로 하는, 약학적 제형의 제조방법.
- 0.5 g, 1.0 g, 1.5 g, 2 g, 3 g, 4 g, 5 g, 6 g, 8 g 및 10 g으로 이루어진 군으로부터 선택된 메살라진 총 투여량을 포함하며, 바람직하게는 포내에 충진된 것을 특징으로 하는, 제 1 항 내지 제 11항 중 어느 한항에 따른 약학적 제형의 제조를 위한, 메살라진의 용도.
- 제 21항에 있어서, 상기 약학적 제형은 장 질환(intestinal bowel disease)(IBD), 바람직하기로는 크론씨 병 또는 궤양성 대장염 치료용인 것을 특징으로 하는, 메살라진의 용도.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46464903P | 2003-04-23 | 2003-04-23 | |
DKPA200300612 | 2003-04-23 | ||
DKPA200300612 | 2003-04-23 | ||
US60/464,649 | 2003-04-23 | ||
EP20030388023 EP1470819A1 (en) | 2003-04-23 | 2003-04-23 | High drug load mesalazine sachet |
EP03388023.8 | 2003-04-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060003362A true KR20060003362A (ko) | 2006-01-10 |
KR100849966B1 KR100849966B1 (ko) | 2008-08-01 |
Family
ID=36655488
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020057020069A KR100849966B1 (ko) | 2003-04-23 | 2004-04-23 | 약물부하가 높은 메살라진 포 |
Country Status (20)
Country | Link |
---|---|
US (3) | US20070042143A1 (ko) |
EP (3) | EP1615619A2 (ko) |
JP (4) | JP2007523664A (ko) |
KR (1) | KR100849966B1 (ko) |
CN (1) | CN1777430B (ko) |
AU (1) | AU2004231316B2 (ko) |
CA (2) | CA2520197A1 (ko) |
CY (1) | CY1115560T1 (ko) |
DK (1) | DK1615648T3 (ko) |
ES (1) | ES2486245T3 (ko) |
HK (2) | HK1083312A1 (ko) |
IL (1) | IL170978A (ko) |
MX (1) | MXPA05011308A (ko) |
NO (1) | NO335375B1 (ko) |
NZ (1) | NZ542591A (ko) |
PL (1) | PL1615648T3 (ko) |
PT (1) | PT1615648E (ko) |
RU (2) | RU2547552C2 (ko) |
SI (1) | SI1615648T1 (ko) |
WO (2) | WO2004093883A2 (ko) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6632429B1 (en) | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
US8282955B2 (en) | 2001-10-15 | 2012-10-09 | Ferring B.V. | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease |
JP2007523664A (ja) | 2003-04-23 | 2007-08-23 | フェリング ベスローテン フェンノートシャップ | 医薬組成物用サシェ |
US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
US7951436B2 (en) | 2006-08-14 | 2011-05-31 | Frito-Lay North America, Inc. | Environmentally-friendly multi-layer flexible film having barrier properties |
US7943218B2 (en) | 2006-08-14 | 2011-05-17 | Frito-Lay North America, Inc. | Environmentally-friendly multi-layer flexible film having barrier properties |
US7645801B2 (en) | 2007-01-29 | 2010-01-12 | Alaven Pharmaceutical Llc | Reduced irritant enema for treatment of inflammatory bowel disease (IBD) |
US20090169622A1 (en) * | 2007-12-27 | 2009-07-02 | Roxane Laboratories, Inc. | Delayed-release oral pharmaceutical composition for treatment of colonic disorders |
US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
WO2009118761A2 (en) * | 2008-03-24 | 2009-10-01 | Bhandari Mohan Harakchand | Metallized paper based lidding material for blister packaging & process thereof |
US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
US9320780B2 (en) | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
PL2318035T3 (pl) | 2008-07-01 | 2019-10-31 | Curemark Llc | Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego |
US10776453B2 (en) | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
WO2010040113A1 (en) | 2008-10-03 | 2010-04-08 | Salix Pharmaceuticals, Ltd. | Compositions and methods for the treatment of bowel diseases with granulated mesalamine |
JP5684725B2 (ja) | 2009-01-06 | 2015-03-18 | キュレロン リミテッド ライアビリティ カンパニー | 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法 |
ES2727746T3 (es) | 2009-01-06 | 2019-10-18 | Galenagen Llc | Composiciones orales para el tratamiento o la prevención de infecciones por E. Coli |
US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
WO2011050135A1 (en) | 2009-10-21 | 2011-04-28 | Curemark Llc | Methods and compositions for the prevention and treatment of influenza |
EP2340812A1 (en) | 2009-12-18 | 2011-07-06 | Ferring International Center S.A. | Granules for pharmaceutical preparations, methods and apparatus for their production |
KR20130102070A (ko) * | 2010-09-10 | 2013-09-16 | 파마젤 게엠베하 | 결정질 5-아미노살리실산의 제조 방법 |
WO2012145651A2 (en) | 2011-04-21 | 2012-10-26 | Curemark, Llc | Compounds for the treatment of neuropsychiatric disorders |
US9040120B2 (en) | 2011-08-05 | 2015-05-26 | Frito-Lay North America, Inc. | Inorganic nanocoating primed organic film |
US9267011B2 (en) | 2012-03-20 | 2016-02-23 | Frito-Lay North America, Inc. | Composition and method for making a cavitated bio-based film |
US9162421B2 (en) | 2012-04-25 | 2015-10-20 | Frito-Lay North America, Inc. | Film with compostable heat seal layer |
US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
MX355373B (es) | 2012-06-23 | 2018-04-17 | Frito Lay North America Inc | Deposicion de revestimientos de oxido inorganico ultra-delgados sobre empaque. |
US9090021B2 (en) | 2012-08-02 | 2015-07-28 | Frito-Lay North America, Inc. | Ultrasonic sealing of packages |
US9149980B2 (en) | 2012-08-02 | 2015-10-06 | Frito-Lay North America, Inc. | Ultrasonic sealing of packages |
CN102784154B (zh) * | 2012-09-01 | 2013-10-09 | 朱文军 | 一种美沙拉嗪肠溶片及其制备方法 |
WO2015159302A2 (en) * | 2014-04-17 | 2015-10-22 | Athena Drug Delivery Solutions Pvt Ltd. | Process for preparation of mesalamine composition and mesalamine composition thereof |
EP3154523B1 (en) * | 2014-06-16 | 2018-11-21 | Valpharma International S.P.A. | Formulation for oral administration containing mesalazine |
EP3162362A1 (de) | 2015-10-30 | 2017-05-03 | Dr. Falk Pharma Gmbh | Optimierte mesalazinhaltige hochdosistablette |
US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
AU2018389797B2 (en) * | 2017-12-20 | 2024-05-02 | Flamel Ireland Limited | Packaged modified release gamma-hydroxybutyrate formulations having improved stability |
TR201722852A2 (tr) | 2017-12-29 | 2019-07-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Mesalazi̇ni̇n oral farmasöti̇k kompozi̇syonlari |
US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
WO2022129003A1 (en) | 2020-12-15 | 2022-06-23 | Dsm Ip Assets B.V. | Multiparticulate solid oral dosage form comprising statin and vitamin e |
US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4638131B1 (ko) | 1966-06-22 | 1971-11-10 | ||
US4085244A (en) * | 1976-02-10 | 1978-04-18 | Champion International Corporation | Balanced orientated flexible packaging composite |
US4360550A (en) * | 1979-09-12 | 1982-11-23 | Toyo Kagaku Kabushiki Kaisha | Composite packing film and packing bag made of the same |
WO1981002671A1 (en) * | 1980-03-20 | 1981-10-01 | Ferring Farma Lab | Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration |
US4960765A (en) | 1980-03-20 | 1990-10-02 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
JPS6048484B2 (ja) | 1980-05-20 | 1985-10-28 | アルザ・コ−ポレ−シヨン | 拡散性活性剤デイスペンサ− |
JPS5758631A (en) | 1980-09-24 | 1982-04-08 | Toyo Jozo Co Ltd | Coating composition |
ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
US4418841A (en) * | 1982-11-23 | 1983-12-06 | American Can Company | Multiple layer flexible sheet structure |
DE3151196A1 (de) | 1981-12-23 | 1983-06-30 | Kurt Heinz Prof. Dr. 7800 Freiburg Bauer | Verfahren zur herstellung von gut loeslichen 5-aminosalicylsaeure-arzneimittelzubereitungen |
US4629657A (en) * | 1982-12-13 | 1986-12-16 | Enron Chemical Company | Biaxially oriented polypropylene film construction for special lamination |
US4489112A (en) * | 1983-03-28 | 1984-12-18 | Ex-Cell-O Corporation | Laminated paperboard container with absorption resistance means, and blank for constructing same |
SE457505B (sv) | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | Laminatbelagd oral farmaceutisk komposition och foerfarande foer dess framstaellning |
NL8502178A (nl) | 1984-08-16 | 1986-03-17 | Sandoz Ag | Nieuwe farmaceutische preparaten. |
US4693395A (en) * | 1984-12-28 | 1987-09-15 | Colgate-Palmolive Company | Ethylene propylene copolymer in a substrate and collapsible dispensing container made therefrom |
US4702905A (en) * | 1985-08-30 | 1987-10-27 | Colgate-Palmolive Company | Packaged dental cream |
US4705680A (en) * | 1986-01-22 | 1987-11-10 | Colgate-Palmolive Company | Stable dental cream in polyethylene or polypropylene container |
US4720473A (en) | 1986-03-10 | 1988-01-19 | Cri International, Inc. | Production of improved catalyst-type particles using length and density grading |
FR2600893B1 (fr) * | 1986-07-01 | 1990-01-12 | Sandoz Lab | Nouvelles compositions pharmaceutiques a base de sels de calcium |
US5254347A (en) | 1988-03-31 | 1993-10-19 | Tanabe Seiyaku Co., Ltd. | Controlled release pharmaceutical preparation and method for producing the same |
US5194464A (en) * | 1988-09-27 | 1993-03-16 | Takeda Chemical Industries, Ltd. | Enteric film and preparatoin thereof |
US5484605A (en) | 1988-11-25 | 1996-01-16 | Henning Berlin Gmbh Chemie-Und Pharmawerk | Agent for treating chronically inflammatory intestinal diseases |
GB8828349D0 (en) * | 1988-12-05 | 1989-01-05 | Du Pont Canada | Film laminate with easy to td tear |
GB8913889D0 (en) | 1989-06-16 | 1989-08-02 | May & Baker Ltd | New compositions of matter |
IT1246382B (it) | 1990-04-17 | 1994-11-18 | Eurand Int | Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon |
US5433982A (en) * | 1990-11-14 | 1995-07-18 | Dai Nippon Printing Co., Ltd. | Composite container having barrier property |
US5316772A (en) * | 1990-12-19 | 1994-05-31 | Solvay & Cie, S.A. (Societe Anonyme) | Bilayered oral pharmaceutical composition with pH dependent release |
GEP19971086B (en) | 1991-02-22 | 1997-12-02 | Tillotts Pharma Ag | Peroral Pharmaceutically Dispensed Form for Selective Introducing of the Medicine into the Intestine |
GB2256587A (en) | 1991-06-11 | 1992-12-16 | American Cyanamid Co | Acetazolamide in sustained release form |
US5472712A (en) | 1991-12-24 | 1995-12-05 | Euroceltique, S.A. | Controlled-release formulations coated with aqueous dispersions of ethylcellulose |
US5474818A (en) * | 1992-05-15 | 1995-12-12 | International Paper | Flexible container with nonstick interior |
JP2607422B2 (ja) * | 1992-09-08 | 1997-05-07 | 呉羽化学工業株式会社 | 内服用吸着剤の分包包装体及びその製造方法 |
JPH0827133B2 (ja) | 1993-07-13 | 1996-03-21 | 不二パウダル株式会社 | 湿潤粉粒体の処理装置 |
US5482718A (en) | 1994-03-23 | 1996-01-09 | Hoffmann-La Roche Inc. | Colon-targeted delivery system |
JPH0880597A (ja) * | 1994-07-14 | 1996-03-26 | Kyodo Printing Co Ltd | 抗菌性積層体、これを用いた袋体、容器および成形カップ |
JPH0826977A (ja) | 1994-07-19 | 1996-01-30 | Tanabe Seiyaku Co Ltd | 溶出制御型経口製剤 |
IT1277663B1 (it) * | 1995-09-28 | 1997-11-11 | Crinos Industria Farmaco | Sospensioni acquose stabili di mesalazina per uso topico |
TR199801158T2 (xx) * | 1995-12-21 | 1998-09-21 | Farmaceutisk Laboratorium Ferring A/S | Ba��rsak hastal�klar� i�in oral farmas�tik kompozisyon. |
US6004581A (en) | 1995-12-21 | 1999-12-21 | Farmaceutisk Laboratorium Ferring A/S | Modified release oral pharmaceutical composition and method for the treatment of bowel diseases |
US6245351B1 (en) | 1996-03-07 | 2001-06-12 | Takeda Chemical Industries, Ltd. | Controlled-release composition |
IL118932A0 (en) | 1996-07-24 | 1996-10-31 | Dexcel Ltd | Controlled release tablets |
AU729206B2 (en) | 1996-07-28 | 2001-01-25 | Biosense, Inc. | Electromagnetic cardiac biostimulation |
WO1998026767A2 (en) | 1996-12-17 | 1998-06-25 | Poli Industria Chimica S.P.A. | Site-specific controlled release dosage formulation for mesalamine |
GB9722426D0 (en) | 1997-10-23 | 1997-12-24 | Univ London Pharmacy | Controlled release formulations |
EP0939037A1 (de) * | 1998-02-26 | 1999-09-01 | Alusuisse Technology & Management AG | Verpackungsmaterial |
EP1079820A1 (en) | 1998-05-19 | 2001-03-07 | Centaur Pharmaceuticals, Inc. | Benzamide therapeutics for the treatment of inflammatory bowel disease |
WO2000014333A1 (en) * | 1998-09-03 | 2000-03-16 | Stora Kopparberg Bergslags Ab (Publ) | Paper or paperboard laminate and method to produce such a laminate |
CO5140079A1 (es) | 1998-10-14 | 2002-03-22 | Novartis Ag | Composicion farmaceutica de liberacion sostenida y metodo para liberar un agente farmaceuticamente activo de liberacion sostenida y metodo para liberar un agente far- maceuticamente activo |
IT1303753B1 (it) | 1998-11-13 | 2001-02-23 | Ct Lab Farm Srl | Composizioni farmaceutiche somministrabili per via orale contenentiun rivestimento gastroresistente a base di polimeri acrilici. |
JP2002535353A (ja) | 1999-01-29 | 2002-10-22 | ロザン ファルマ ゲゼルシャフトミットベシュレンクテルハフツンク | 医薬品組成物 |
ITMI991316A1 (it) | 1999-06-14 | 2000-12-14 | Cip Ninety Two 92 S A | Composizioni farmaceutiche orali a rilascio modificato di mesalazina |
JP2001055322A (ja) | 1999-08-18 | 2001-02-27 | Tanabe Seiyaku Co Ltd | パルス放出型製剤 |
JP4439629B2 (ja) * | 1999-09-14 | 2010-03-24 | 久光製薬株式会社 | 包装用袋体 |
US6199698B1 (en) * | 1999-12-03 | 2001-03-13 | Alusuisse Technology & Management, Ltd. | Pharmaceutical packaging with separation means |
US6627223B2 (en) | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
IT1318376B1 (it) * | 2000-03-07 | 2003-08-25 | Pharmatec Internat S R L | Forme solide orali a rilascio controllato contenenti mesalazina comeprincipio attivo. |
DE10013030A1 (de) | 2000-03-17 | 2001-09-20 | Roehm Gmbh | Verwendung eines Copolymers zur Herstellung einer Arzneiform zur Therapie von Colitis ulcerosa und verwendungsgemäße Arzneiform |
IT1318625B1 (it) * | 2000-07-14 | 2003-08-27 | Roberto Valducci | Formulazioni farmaceutiche solide orali a rilascio multifasicoph-dipendente. |
JP2004507487A (ja) * | 2000-08-29 | 2004-03-11 | メファ・アクチェンゲゼルシャフト | 腸疾患治療薬 |
US20020177579A1 (en) * | 2000-11-06 | 2002-11-28 | Larry Augsburger | Extended release formulation of water-soluble drugs |
JP4726414B2 (ja) | 2001-10-15 | 2011-07-20 | フェリング ベスローテン フェンノートシャップ | 潰瘍性大腸炎およびクローン病の治療に使用するための5−アミノサリチル酸を含む医薬組成物の調製方法 |
US8282955B2 (en) | 2001-10-15 | 2012-10-09 | Ferring B.V. | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicylic acid for use in treatment of ulcerative colitis and Crohn's disease |
US7025205B2 (en) * | 2002-06-26 | 2006-04-11 | Aventis Pharma Limited | Method and packaging for pressurized containers |
SI1565258T1 (sl) | 2002-11-26 | 2012-04-30 | Univ Gent | Postopek in naprava za neprekinjeno mokro granulacijo materiala v prahu |
JP2007523664A (ja) | 2003-04-23 | 2007-08-23 | フェリング ベスローテン フェンノートシャップ | 医薬組成物用サシェ |
EP1547601A1 (en) | 2003-12-23 | 2005-06-29 | Ferring B.V. | Coating method |
EP2123629A1 (en) * | 2007-02-22 | 2009-11-25 | Ajinomoto Co., Inc. | Method for purifying 4-hydroxyisoleucine |
EP2340812A1 (en) | 2009-12-18 | 2011-07-06 | Ferring International Center S.A. | Granules for pharmaceutical preparations, methods and apparatus for their production |
-
2004
- 2004-04-22 JP JP2006505232A patent/JP2007523664A/ja active Pending
- 2004-04-22 US US10/553,630 patent/US20070042143A1/en not_active Abandoned
- 2004-04-22 WO PCT/EP2004/004280 patent/WO2004093883A2/en active Application Filing
- 2004-04-22 EP EP04728807A patent/EP1615619A2/en not_active Withdrawn
- 2004-04-22 CA CA002520197A patent/CA2520197A1/en not_active Abandoned
- 2004-04-23 ES ES04729050.7T patent/ES2486245T3/es not_active Expired - Lifetime
- 2004-04-23 MX MXPA05011308A patent/MXPA05011308A/es active IP Right Grant
- 2004-04-23 SI SI200432177T patent/SI1615648T1/sl unknown
- 2004-04-23 PT PT47290507T patent/PT1615648E/pt unknown
- 2004-04-23 CA CA2520026A patent/CA2520026C/en not_active Expired - Lifetime
- 2004-04-23 RU RU2009111609/15A patent/RU2547552C2/ru active
- 2004-04-23 EP EP14163036.8A patent/EP2756844A1/en not_active Withdrawn
- 2004-04-23 EP EP04729050.7A patent/EP1615648B1/en not_active Expired - Lifetime
- 2004-04-23 US US10/553,629 patent/US8858992B2/en active Active
- 2004-04-23 DK DK04729050.7T patent/DK1615648T3/da active
- 2004-04-23 KR KR1020057020069A patent/KR100849966B1/ko active IP Right Grant
- 2004-04-23 AU AU2004231316A patent/AU2004231316B2/en not_active Expired
- 2004-04-23 WO PCT/EP2004/004297 patent/WO2004093884A2/en active Application Filing
- 2004-04-23 NZ NZ542591A patent/NZ542591A/en unknown
- 2004-04-23 RU RU2005131492/15A patent/RU2005131492A/ru unknown
- 2004-04-23 PL PL04729050T patent/PL1615648T3/pl unknown
- 2004-04-23 JP JP2006505237A patent/JP4753864B2/ja not_active Expired - Lifetime
- 2004-04-23 CN CN2004800107906A patent/CN1777430B/zh not_active Expired - Lifetime
-
2005
- 2005-09-19 IL IL170978A patent/IL170978A/en active IP Right Grant
- 2005-11-23 NO NO20055534A patent/NO335375B1/no unknown
-
2006
- 2006-04-26 HK HK06104975.5A patent/HK1083312A1/xx not_active IP Right Cessation
-
2009
- 2009-12-08 JP JP2009278169A patent/JP2010090146A/ja active Pending
-
2010
- 2010-02-26 JP JP2010041157A patent/JP2010179109A/ja not_active Withdrawn
-
2014
- 2014-08-04 CY CY20141100596T patent/CY1115560T1/el unknown
- 2014-09-11 US US14/483,695 patent/US9402815B2/en not_active Expired - Lifetime
- 2014-12-09 HK HK14112393.2A patent/HK1198917A1/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100849966B1 (ko) | 약물부하가 높은 메살라진 포 | |
KR101141508B1 (ko) | 판토프라졸 복합 미립자 제형 | |
TWI453203B (zh) | 包含bibw2992之新固體醫藥調配劑 | |
RU2221553C2 (ru) | Способ изготовления округлых гранул | |
JP5732572B2 (ja) | 味覚遮蔽・即放性フェキソフェナジン・マイクロカプセルを製造する方法 | |
SK110299A3 (en) | Pharmaceutical formulations comprising amoxocyllin and clavulanate, preparation method and use thereof | |
CA2462905C (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease | |
JP2014516961A (ja) | 多粒子医薬組成物 | |
EP1470819A1 (en) | High drug load mesalazine sachet | |
US20130115282A1 (en) | Polyvalent polymeric matrix for modified release solid oral preparations and method of preparation thereof | |
RU2814336C1 (ru) | Высокодозная композиция транексамовой кислоты и способы ее получения | |
JPH02193914A (ja) | マトリックス型持続性製剤 | |
BR102023006993A2 (pt) | Composição de ácido tranexâmico com alta dosagem em múltiplas camadas e processo de sua preparação | |
AU2002210386B2 (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and Crohn's disease | |
Singh | Formulation and evaluation of sustained release dosage form of selected drug using release eudragits | |
EP2749273A1 (en) | Solid oral preparation with modified release | |
MXPA00008620A (en) | Pharmaceutical composition of topiramate | |
AU2002210386A1 (en) | Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and Crohn's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
J201 | Request for trial against refusal decision | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
B601 | Maintenance of original decision after re-examination before a trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20071106 Effective date: 20080509 |
|
S901 | Examination by remand of revocation | ||
GRNO | Decision to grant (after opposition) | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20130701 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20140703 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160630 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20170704 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20180718 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20190724 Year of fee payment: 12 |